Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (31-40 of 740) with videos related to

Pageof 74
Sort By:
The Lancet. Oncology|September 25, 2010
Intravenous pamidronate for myeloma bone disease: can the dose be lowered?Evangelos Terpos, Meletios A Dimopoulos
Expert Opinion on Pharmacotherapy|February 21, 2007
The evolving role of lenalidomide in the treatment of hematologic malignanciesEfstathios Kastritis, Meletios A Dimopoulos
Nature Clinical Practice. Oncology|September 10, 2008
Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myelomaMeletios A Dimopoulos, Efstathios Kastritis
The Lancet. Oncology|July 21, 2011
Zoledronic acid for all patients with newly diagnosed multiple myeloma?Evangelos Terpos, Meletios A Dimopoulos
Blood|July 30, 2011
Bortezomib for AL amyloidosis: moving forwardMeletios A Dimopoulos, Efstathios Kastritis
European Journal of Internal Medicine|February 14, 2004
Angiogenesis in human cancer: implications in cancer therapyAristotle Bamias, Meletios A. Dimopoulos
Blood|August 26, 2017
Daratumumab combinations: what can we learn?Efstathios Kastritis, Meletios A Dimopoulos
Best Practice & Research. Clinical Haematology|December 12, 2007
Thalidomide in the treatment of multiple myelomaEfstathios Kastritis, Meletios A Dimopoulos
European Urology|January 19, 2008
Editorial comment on: new treatment approaches for prostate cancer based on peptide analoguesAristotelis Bamias, Meletios A Dimopoulos
British Journal of Haematology|April 25, 2017
Prognosis and risk assessment in AL amyloidosis - There and back againEfstathios Kastritis, Meletios A Dimopoulos
Pageof 74

Showing results (31-40 of 740) with videos related to

Sort By:
Pageof 74
The Lancet. Oncology|September 25, 2010
Intravenous pamidronate for myeloma bone disease: can the dose be lowered?Evangelos Terpos, Meletios A Dimopoulos
Expert Opinion on Pharmacotherapy|February 21, 2007
The evolving role of lenalidomide in the treatment of hematologic malignanciesEfstathios Kastritis, Meletios A Dimopoulos
Nature Clinical Practice. Oncology|September 10, 2008
Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myelomaMeletios A Dimopoulos, Efstathios Kastritis
The Lancet. Oncology|July 21, 2011
Zoledronic acid for all patients with newly diagnosed multiple myeloma?Evangelos Terpos, Meletios A Dimopoulos
Blood|July 30, 2011
Bortezomib for AL amyloidosis: moving forwardMeletios A Dimopoulos, Efstathios Kastritis
European Journal of Internal Medicine|February 14, 2004
Angiogenesis in human cancer: implications in cancer therapyAristotle Bamias, Meletios A. Dimopoulos
Blood|August 26, 2017
Daratumumab combinations: what can we learn?Efstathios Kastritis, Meletios A Dimopoulos
Best Practice & Research. Clinical Haematology|December 12, 2007
Thalidomide in the treatment of multiple myelomaEfstathios Kastritis, Meletios A Dimopoulos
European Urology|January 19, 2008
Editorial comment on: new treatment approaches for prostate cancer based on peptide analoguesAristotelis Bamias, Meletios A Dimopoulos
British Journal of Haematology|April 25, 2017
Prognosis and risk assessment in AL amyloidosis - There and back againEfstathios Kastritis, Meletios A Dimopoulos
Pageof 74